生物製品市場研究

---

In the fast-paced world of biologics, staying ahead of the curve is crucial. Biologics market research provides the data and insights necessary for businesses to thrive.

Are you looking to gain a competitive edge in the dynamic field of biologics? Biologics market research provides critical insights into market trends, regulatory landscapes, and competitive dynamics. These insights enable companies to develop effective strategies, optimize their operations, and achieve sustainable growth in the biologics market.

What are Biologics?

Biological products include blood, vaccines, somatic cells, and tissues. Gene therapy, blood components, and recombinant therapeutic proteins also fall under that umbrella. Biologics come from these products’ proteins, sugars, or nucleic acids. They can be complex mixes of these substances or living entities such as tissues and cells. Most Biologics are compound mixtures that are not easy to identify. In this way, they differ from most drugs. The average drug comes from chemical synthesis; the makers know their structure.

Biologics are some of the most advanced therapies you will find anywhere. Doctors use them to treat many diseases and conditions. Examples of medical uses for Biologics include:

• Rheumatoid arthritis
• Various cancers
• Crohn’s Disease
• Heart attack
• Multiple sclerosis
• Lupus
• Chronic migraine
• Anemia
• Allergic asthma
• Cystic fibrosis

Biologics Market Research: How Leading Manufacturers Win in Specialty Therapeutics

Biologics now drive the majority of new specialty pharma revenue, and the firms gaining share share one trait: disciplined intelligence. Biologics market research separates teams that price into resistance from teams that secure formulary wins on launch.

The category rewards precision. Molecules compete on indication-level efficacy, payer evidence, injection device experience, and cold chain reliability. Generic frameworks miss this. The winners commission intelligence built around the mechanism of action, the prescriber decision tree, and the payer evidence threshold for each target indication.

Why Biologics Market Research Demands a Different Operating Model

Small molecule playbooks transfer poorly. Biologics carry manufacturing complexity, narrow patient subpopulations, biomarker-driven prescribing, and biosimilar competitive intelligence requirements that begin years before loss of exclusivity. The intelligence model has to match.

Three structural realities shape the work. Prescribing concentrates among a small set of pulmonologists, rheumatologists, oncologists, or dermatologists per market. Payer access decisions hinge on real-world evidence and HTA submission evidence rather than pivotal trial data alone. Patient adherence depends on device usability, site of care economics, and specialty pharmacy distribution.

SIS International Research has found that competitive position in biologics correlates more tightly with KOL mapping depth and payer value story clarity than with headline efficacy data. Asthma biologics provide a clear example: IL-5 and IgE class entrants with similar clinical profiles separated on prescriber confidence, eosinophil biomarker positioning, and injection site experience rather than absolute exacerbation reduction.

The Intelligence Stack That Drives Biologics Launch Success

High-performing teams build a layered intelligence stack rather than a single tracker. Each layer answers a different commercial question and feeds a different function inside the launch organization.

Source: SIS International Research

The stack matters because the questions arrive sequentially. Indication prioritization governs the trial program. KOL mapping shapes the publication plan. Payer value story drafts begin two years before approval. Patient journey work informs hub services. Biosimilar defense begins at peak sales, not at patent cliff.

Where Conventional Research Falls Short and What Replaces It

Standard syndicated reports estimate market size and rank competitors. They rarely reveal why a pulmonologist switched from omalizumab to dupilumab in moderate-to-severe atopic dermatitis with comorbid asthma, or why a German sickness fund tightened prior authorization on a specific IL-5 inhibitor. Those answers come from primary work with the actual decision makers.

Leading manufacturers fund three categories of primary intelligence the syndicated reports cannot replicate. Structured specialist interviews across the US, Germany, Japan, and the UK quantify switching triggers and unmet need by line of therapy. Payer dossier reviews simulate HTA submission evidence against the live reference cases. Patient ethnography captures injection experience, caregiver burden, and the operational pain points that drive discontinuation.

In structured expert interviews conducted by SIS International with senior pulmonologists and allergists across the US, Germany, and Japan, prescriber preference inside the IL-5 class shifted on three non-clinical factors: dosing interval, autoinjector reliability, and the speed of specialty pharmacy fulfillment. Headline efficacy was treated as table stakes once a molecule cleared the eosinophil threshold.

The Global Dimension: Why Multi-Country Design Compounds Returns

Biologics commercialize across regulatory regimes that price and reimburse differently. The FDA, EMA, PMDA, MHRA, NMPA, and ANVISA evaluate the same molecule against different evidence bars. A research design that treats the US as the anchor and bolts on country supplements produces blind spots in the markets that often determine global net price.

Germany’s AMNOG benefit assessment, England’s NICE appraisal, and Japan’s Chuikyo pricing all set reference points other payers watch. France’s transparency commission scoring shapes EU pricing corridors. Disciplined teams design the global research program backward from the toughest HTA submission evidence requirement, not forward from the US label.

SIS International’s biologics work across the US, EU5, Japan, and emerging Asia has shown that launch sequencing decisions made on US-only research overestimate ex-US net price by meaningful margins. Multi-country payer panels run in parallel produce a defensible price corridor and identify the indications where evidence generation will move the access needle.

The SIS Biologics Intelligence Framework

The framework below organizes the work most Fortune 500 biopharma teams now commission across the lifecycle. It is method-led rather than topic-led, which keeps the intelligence tied to actual launch and defense decisions.

Source: SIS International Research

What Separates the Manufacturers That Win Share

The pattern is consistent across asthma, atopic dermatitis, IBD, plaque psoriasis, and oncology biologics. Manufacturers that gain share treat market research as a continuous instrument rather than a launch event. They refresh KOL mapping quarterly, rerun payer value story testing after every competitive label expansion, and run patient ethnography on a rolling cycle.

They also integrate the intelligence. Medical affairs, market access, marketing, and competitive intelligence read from the same evidence base. The integration prevents the common failure mode in which the brand team prices for a value story the payer team has already abandoned in dossier negotiations.

Biologics market research, done with this discipline, is the single highest-leverage commercial investment a specialty manufacturer makes. The ratio of research spend to peak sales protected is favorable across every major class SIS has profiled.

Where Senior Teams Take This Next

The teams getting biologics market research right are now extending the model into bispecifics, cell and gene therapies, and the next biosimilar wave. The methods scale. The discipline of asking the right question at the right lifecycle stage, to the right specialist or payer, in the right country, transfers cleanly into the modalities that will define the next decade of specialty therapeutics.

關於 SIS 國際

SIS國際 提供定量、定性和策略研究。我們為決策提供數據、工具、策略、報告和見解。我們也進行訪談、調查、焦點小組和其他市場研究方法和途徑。 聯絡我們 為您的下一個市場研究項目。